The concern centers not on the trial results themselves, but on the limitations of the data
Nausea, vomiting, constipation, and reduced appetite are common during dose escalation and typically improve within 12 weeks at each new dose
Ok so that was the first big problem with GLP-1 agonists
Other ingredients Purified water, phosphoric acid, natural flavors, stevia leaf extract, potassium sorbate, sodium benzoate
SPL UNCLASSIFIED SECTION Never Share a MOUNJARO KwikPen Between Patients Advise patients that they must never share a MOUNJARO KwikPen with another person, even if the pen needle is changed, because doing so carries a risk for transmission of blood-borne pathogens [see Warnings and Precautions (5.10)]